JPRN-UMIN000026730未知未知
sefulness of FDG-PET/CT to predict the response after pembrolizumab in patients with PD-L1 positive advanced non-small cell lung cancer - FDG-PET/CT and prediction of pembrolizumab in lung cancer
适应症
试验速览
- 阶段
- 未知
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Pregnant woman 2) Patients with obvious interstitial pneumonia or pulmonary fibrosis in the chest X-ray. 3) Patients with collagen vascular disease or autoimmune diseases 4) Other cases attending physician it is determined unsuitable for registration of the study
研究者
相似试验
尚未招募
不适用
sefulness of FDG-PET/CT to predict the response after anti-PD-1 antibody in patients with previously treated advanced non-small cell lung cancer: a multi-institutional studyPreviously treated advanced non-small cell lung cancerJPRN-UMIN000031009Gunma University120
招募中
不适用
sefulness of FDG-PET/CT to predict the response after nivolumab in patients with previously treated advanced non-small cell lung cancerPreviously treated advanced non-small cell lung cancerJPRN-UMIN000020814Gunma30
已完成
不适用
sefulness of FDG-PET/CT examination as prediction of effect of immune checkpoint inhibitors in patients with non-small cell lung cancer : a pilot studyadvanced and recurrent non-small cell lung cancerJPRN-UMIN000031095Kansai Medical University30
进行中（未招募）
不适用
se of the PET-Scan examination in the evaluation of the treatment of patients diagnosed with Head and Neck CancerScamous Cell- Carcinoma of Head and NeckNeoplasmsPositron Emission Tomography Computed TomographyC04.557.470.200.400E01.370.350.350.800.700.500RBR-9wwstdAC Camargo Cancer Center
招募中
1 期
FDG-PET/CT versus conventional CT for response monitoring in metastatic breast cancer: A pilot study for a randomized clinical trial (MONITOR-PILOT)Metastatic breast cancerCTIS2023-506550-20-00Odense University Hospital30